Gaowei Medicine Secures Hundreds of Millions in Pre-A Funding Round, Focusing on AI Drug Discovery

Stock News10-14

According to IT Juzi, Gaowei Medicine has announced the completion of a Pre-A funding round worth hundreds of millions of yuan.

The round was co-led by Huatai金斯瑞基金 and Oriental Jiafu, with participation from Guofang Venture Capital, Ruili Investment, and Chuchang Fund. Existing shareholders Xinghua Dingli, West Lake Innovation, and GF Xinde continued to increase their investments, while Qifeng Capital served as the exclusive financial advisor for this round.

Public records show that Gaowei Medicine (Hangzhou) Co., Ltd. was established in 2022 and is dedicated to building a "high-dimensional biology + AI drug design" platform to provide innovative solutions for major diseases such as neurodegenerative disorders and tumors.

Its core pipeline, GW-01, is the first globally pioneering small molecule drug from the company's AI target discovery platform to enter clinical trials. It targets cancers activated by the Notch pathway. Relying on its self-built GROOVY platform, the company discovered novel targets and mechanisms of action. Both Chinese and U.S. clinical applications received accelerated approval, and Phase I clinical trials have been initiated and officially enrolled at multiple centers.

This funding round will support the development of the company's AI target discovery platform and external collaborations, the clinical research of GW-01, and preclinical research for new pipelines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188501977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-14 17:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188501977","market":"sg","top_or_hot":-1,"title":"Gaowei Medicine Secures Hundreds of Millions in Pre-A Funding Round, Focusing on AI Drug Discovery","media":"Stock News","content":"<p>According to IT Juzi, <b>Gaowei Medicine</b> has announced the completion of a Pre-A funding round worth hundreds of millions of yuan.<br><br>The round was co-led by <b>Huatai金斯瑞基金</b> and <b>Oriental Jiafu</b>, with participation from <b>Guofang Venture Capital</b>, <b>Ruili Investment</b>, and <b>Chuchang Fund</b>. Existing shareholders <b>Xinghua Dingli</b>, <b>West Lake Innovation</b>, and <b>GF Xinde</b> continued to increase their investments, while <b>Qifeng Capital</b> served as the exclusive financial advisor for this round.<br><br>Public records show that <b>Gaowei Medicine (Hangzhou) Co., Ltd.</b> was established in 2022 and is dedicated to building a \"high-dimensional biology + AI drug design\" platform to provide innovative solutions for major diseases such as neurodegenerative disorders and tumors.<br><br>Its core pipeline, <b>GW-01</b>, is the first globally pioneering small molecule drug from the company's AI target discovery platform to enter clinical trials. It targets cancers activated by the Notch pathway. Relying on its self-built <b>GROOVY</b> platform, the company discovered novel targets and mechanisms of action. Both Chinese and U.S. clinical applications received accelerated approval, and Phase I clinical trials have been initiated and officially enrolled at multiple centers.<br><br>This funding round will support the development of the company's AI target discovery platform and external collaborations, the clinical research of GW-01, and preclinical research for new pipelines.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gaowei Medicine Secures Hundreds of Millions in Pre-A Funding Round, Focusing on AI Drug Discovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGaowei Medicine Secures Hundreds of Millions in Pre-A Funding Round, Focusing on AI Drug Discovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-14 17:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to IT Juzi, <b>Gaowei Medicine</b> has announced the completion of a Pre-A funding round worth hundreds of millions of yuan.<br><br>The round was co-led by <b>Huatai金斯瑞基金</b> and <b>Oriental Jiafu</b>, with participation from <b>Guofang Venture Capital</b>, <b>Ruili Investment</b>, and <b>Chuchang Fund</b>. Existing shareholders <b>Xinghua Dingli</b>, <b>West Lake Innovation</b>, and <b>GF Xinde</b> continued to increase their investments, while <b>Qifeng Capital</b> served as the exclusive financial advisor for this round.<br><br>Public records show that <b>Gaowei Medicine (Hangzhou) Co., Ltd.</b> was established in 2022 and is dedicated to building a \"high-dimensional biology + AI drug design\" platform to provide innovative solutions for major diseases such as neurodegenerative disorders and tumors.<br><br>Its core pipeline, <b>GW-01</b>, is the first globally pioneering small molecule drug from the company's AI target discovery platform to enter clinical trials. It targets cancers activated by the Notch pathway. Relying on its self-built <b>GROOVY</b> platform, the company discovered novel targets and mechanisms of action. Both Chinese and U.S. clinical applications received accelerated approval, and Phase I clinical trials have been initiated and officially enrolled at multiple centers.<br><br>This funding round will support the development of the company's AI target discovery platform and external collaborations, the clinical research of GW-01, and preclinical research for new pipelines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"","article_id":"1188501977","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188501977","pubTimestamp":1791970459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to IT Juzi, Gaowei Medicine has announced the completion of a Pre-A funding round worth hundreds of millions of yuan.The round was co-led by Huatai金斯瑞基金 and Oriental Jiafu, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIPO":"Defiance AI and Power Infrastructure ETF","AGIX":"通用人工智能 ETF-AGIX","BK1191":"制药","ARTY":"ISHARES FUTURE AI & TECH ETF","BK1515":"抗疫概念","QTOC":"Innovator Growth Accelerated Plus ETF - October","BK1161":"生物科技","09939":"开拓药业-B","BK1574":"生物医药B类股","01477":"欧康维视生物-B","VTHR":"Vanguard Russell 3000 ETF"},"translate_title":"高威医药获数亿Pre-A轮融资，聚焦AI药物发现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"VTHR":1,"CHAT":1,"01477":1,"QTOC":1,"ARTY":1,"AIPO":1,"AGIX":1,"09939":1},"content_text":"According to IT Juzi, Gaowei Medicine has announced the completion of a Pre-A funding round worth hundreds of millions of yuan.The round was co-led by Huatai金斯瑞基金 and Oriental Jiafu, with participation from Guofang Venture Capital, Ruili Investment, and Chuchang Fund. Existing shareholders Xinghua Dingli, West Lake Innovation, and GF Xinde continued to increase their investments, while Qifeng Capital served as the exclusive financial advisor for this round.Public records show that Gaowei Medicine (Hangzhou) Co., Ltd. was established in 2022 and is dedicated to building a \"high-dimensional biology + AI drug design\" platform to provide innovative solutions for major diseases such as neurodegenerative disorders and tumors.Its core pipeline, GW-01, is the first globally pioneering small molecule drug from the company's AI target discovery platform to enter clinical trials. It targets cancers activated by the Notch pathway. Relying on its self-built GROOVY platform, the company discovered novel targets and mechanisms of action. Both Chinese and U.S. clinical applications received accelerated approval, and Phase I clinical trials have been initiated and officially enrolled at multiple centers.This funding round will support the development of the company's AI target discovery platform and external collaborations, the clinical research of GW-01, and preclinical research for new pipelines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188501977","isCrawlerRequest":true}